Revvity, Inc. RVTY announced the launch of the in-vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark on Oct. 2. The assay will likely enable accurate genotyping of ...

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and ...

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s “With the introduction of new disease-modifying drugs for treating Alzheimer’s, ...

This milestone allows DiamiR to offer its validated APOE Genotyping molecular testing in a variety of biological samples, such as blood, buccal swab, saliva, and tissue, through its Clinical ...

A new research paper was published in Aging (Aging-US) Volume 17, Issue 5, on May 3, 2025, titled "APOE genotype and biological age impact inter-omic associations related to bioenergetics." In this ...

Since July 2023, three anti-amyloid medications have been FDA-approved for the treatment of Alzheimer’s disease with more in development. A potential and serious side effect of anti-amyloid ...

Aptorum Group shares skyrocketed as New York State Department of Health approved a genotyping test from DiamiR Biosciences, which is merging with Aptorum. The stock more than doubled to $3.37 and is ...

Revvity, Inc., announced today the launch of the in-vitro diagnostic EURORealTime ™ APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene.